Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
New York State’s largest health system adopts Philips patient monitoring platform to drive integration and innovation for a better patient and staff experience and improved outcomes
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
70+ CXOs from leading healthcare institutions across India attended the confluence at Mumbai
The facility is over 79,000 square feet and is equipped with packaging lines
Subscribe To Our Newsletter & Stay Updated